Approaches to the early treatment of invasive fungal infection

Leukemia and Lymphoma

Volumn 51, Issue 9, 2010, Pages 1623-1631

  Ito, James I ^a   Kriengkauykiat, Jane ^b   Dadwal, Sanjeet S ^a   Arfons, Lisa M ^c   Lazarus, Hillard M ^c  

^a Division of Infectious Diseases   (United States)

^b Case Western Reserve University ^*  (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

candidemia; early treatment; Invasive fungal infection; mold

Indexed keywords

AMIODARONE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CYTOCHROME P450; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NIFEDIPINE; POSACONAZOLE; QUINOLONE; RAPAMYCIN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ASPERGILLOSIS; ASPERGILLUS; BRAIN; BRONCHOSCOPY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDIASIS; CENTRAL NERVOUS SYSTEM; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOMEGALOVIRUS; DYSPNEA; FEVER; FUSARIUM; HEADACHE; HEART VALVE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HEMOPTYSIS; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; INCIDENCE; LIVER; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NEEDLE BIOPSY; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCEDOSPORIUM; SINUS CONGESTION; SPLEEN; SYSTEMIC MYCOSIS; THORACOSCOPY; THORAX PAIN; ZYGOMYCETES;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, INVASIVE; HEMATOLOGIC NEOPLASMS; HUMANS;

EID: 77956336424     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.496504     Document Type: Review

References (71)

1. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49: 3640-3645.
2. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31.
3. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609-622.
4. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-147.
5. von Eiff M, Roos N, Schulten R, Hesse M, Zühlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995;62:341-347.
6. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917.
7. Pappas PG. Prosective surveillance for invasive fungal infections in solid organ and stem cell transplant recipients. An overview of TRANSNET. Paper presented at Focus on Fungal Infections 17. 7-9 March 2007. San Diego, CA, USA.
8. Michellet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 2009;27: 3398-3409.
9. Park BJ, Morrison VA, Kontoyiannis DP, et al. TRANSNET Investigators. Description of very-late (VL) invasive mould infections (IMI) among hematopoietic stem cell transplant (HSCT) recipients reported in TRANSNET. Paper presented at 43rd Annual Meeting of the Infectious Disease Society of America (Abstract 745). 6-9 October 2005. San Francisco, CA, USA.
10. Marr KA. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Curr Opinion Infect Dis 2008;21:409-414.
11. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin N Am 2006;20:581-607.
12. Park BJ, Pappas PG, Marr KA, et al. Recent epidemiology of zygomycosis among organ transplant and stem cell transplant recipients: results from the TRANSNET surveillance network. Paper presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Abstract M-618). 17-20 September 2007. Chicago, IL, USA.
13. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
14. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552.
15. Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia 2009; 168:299-311.
16. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs fluconazole or intraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359.
17. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991;324:1005-1011.
18. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-558.
19. Boeckh M, Ljungman P. How I treat cytomegalovrius in hematopoietic cell transplant recipients. Blood 2009;113: 5711-5719.
20. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnositic adjuncts. Clin Infect Dis 2007;44:402-409.
21. Maertens J, Theunissen K, Lodewyck T, Lagrou K, Van Eldere J. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007;50:2-17.
22. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE; Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Infect Dis 2003;51:45-52.
23. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 2009;47:1942-1946.
24. White T, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.
25. Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol 2008;25:101-106.
26. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-618.
27. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005;40:S414-S421.
28. McTaggart B, McKechnie M, Gin A, Bombassaro A, Lui E, Carle S. Comparative nephrotoxic effects of amphotericin B lipid complex and liposomal amphotericin B in patients with hematological malignancy. Paper presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Abstract M-965). 14-17 September 2003. Chicago, IL, USA.
29. Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001;21:1107-1114.
30. Wingard JR, White MH, Anaissie EJ, Raffalli J, Goodman J, Arrieta AC. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empiricial treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-1163.
31. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295-1320.
32. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79.
33. Manavathu EK, Cutright JL, Chandrasekar PH. Organismdependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018-3021.
34. Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999;43: 169-170.
35. Diekema D, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voricaonzole, and amphotericin B against 448 recent clincial isolates of filamentous fungi. J Clin Microbiol 2003;46:1581-1582.
36. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008;46:567-573.
37. Galgiani JN, Lewis ML. In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother 1997;41: 180-183.
38. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;359:1135-1144.
39. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994;34:659-668.
40. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002;46:1704-1713.
41. Lass-Florl C, Mayr A, Perkhofer S, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008;52:3637-3641.
42. Vfend [package insert]. March 2008. Pfizer Inc., New York, NY, USA.
43. Diflucan [package insert]. March 2008. Pfizer Inc., New York, NY, USA.
44. Noxafil [package insert]. February 2009. Schering-Plough, Kenilworth, NJ, USA.
45. Sporanox [package insert]. March 2009. Ortho-McNeil- Janssen Pharmaceuticals, Inc., Raritan, NJ, USA.
46. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stemcell transplant recipients. Bone Marrow Transplant 2005;35: 509-513.
47. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med 2003;138:705-713.
48. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103: 1527-1533.
49. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-1572.
50. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-211.
51. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451-456.
52. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:659-666.
53. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12.
54. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46:235-243.
55. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002;35:1273-1275.
56. Moore CB, Denning DW. Tolerance and fungicidality in vitro of caspofungin, micafungin and anidulafungin against Candida guilliermondii. Paper presented at 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Abstract M-230). 27-30 September 2002. San Diego, CA, USA.
57. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002;46:1773-1780.
58. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opinion Infect Dis 2001;14:685-691.
59. Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2004;2:499-508.
60. Chandrasekar P, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2005;42:1171-1178.
61. Philip A, Odabasi Z, Rodriguez J, et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005;49:3572-3574.
62. Luque JC, Clemons KV, Stevens DA. Effiacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003;47:1452-1455.
63. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002;46:3039-3041.
64. Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006;57:705-708.
65. Eraxis [package insert]. May 2007. Pfizer Inc., New York, NY, USA.
66. Mycamine [package insert]. January 2008. Astellas Pharma US, Inc., Deerfield, IL, USA.
67. Cancidas [package insert]. June 2009. Merck & Co., Inc., Whitehouse Station, NY, USA.
68. The NCCN Clinical Practice Guidelines in OncologyTM Prevention and Treatment of Cancer-Related Infections (Version V.1.2009) [Internet]. National Comprehensive Cancer Network, Inc. Available at: http://www.NCCN.org/
69. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535.
70. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360.
71. Thursky KA, Playford EG, Seymour JF, et al. Recommendations for the treatment of established fungal infections. Intern Med J 2008;38:496-520.